Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1985-6-3
pubmed:abstractText
Prophylactic phenytoin (DPH) has been evaluated in 20 patients undergoing diagnostic myelography. DPH (0.75 g) was ingested at 20.00 h the night before and 0.5 g at 08.00 h on the morning of the procedure. Total DPH concentrations at myelography (mean +/- s.d.: 12.7 +/- 4.3 mg l-1; range 6.3-21.5 mg l-1) correlated with CSF values (1.3 +/- 0.46 mg l-1; range 0.7-2.2 mg l-1; r = 0.83, P less than 0.001). DPH protein binding at that time varied two-fold (9.2-18.5%) and free drug levels (1.7 +/- 0.6 mg l-1) correlated with CSF (r = 0.83, P less than 0.001) and total (r = 0.89, P less than 0.001) plasma DPH concentrations. There were significant negative correlations between patient weight (n = 17) and total (r = 0.57, P less than 0.05) and CSF (r = -0.55, P less than 0.05) DPH concentrations at myelography. Total plasma DPH levels 8 h (14.5 +/- 3.9 mg l-1; range 7.3-20.6 mg l-1) and 24 h (12.3 +/- 3.8 mg l-1; range 5.0-19.8 mg l-1) after myelography were largely within the 'therapeutic range' of 10-20 mg l-1 for the drug. No patient suffered a seizure although, in two, spike discharges were seen on a post-myelography electroencephalogram. A simple regime involving two doses of DPH would provide acceptable plasma CSF concentrations as a basis for controlled studies in seizure prophylaxis following neuroradiological investigations involving intrathecal contrast.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-1095281, http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-115679, http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-168065, http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-383353, http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-4815953, http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-4969740, http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-49797, http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-6135483, http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-6347033, http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-6347141, http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-6414500, http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-6419764, http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-6644321, http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-6749368, http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-6762701, http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-6823029, http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-7066170, http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-7104186, http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-7471615, http://linkedlifedata.com/resource/pubmed/commentcorrection/3986076-883764
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0306-5251
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
161-8
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1985
pubmed:articleTitle
Protein binding and CSF penetration of phenytoin following acute oral dosing in man.
pubmed:publicationType
Journal Article